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Abstract
Background: Congenital rubella syndrome (CRS) is associated with several negative outcomes, including autism
spectrum disorders (ASDs). The objective of this study was to estimate the numbers of CRS and ASD cases
prevented by rubella vaccination in the United States from 2001 through 2010.
Methods: Prevention estimates were calculated through simple mathematical modeling, with values of model
parameters determined from published literature. Model parameters included pre-vaccine era CRS incidence,
vaccine era CRS incidence, the number of live births per year, and the percentage of CRS cases presenting with an
ASD.
Results: Based on our estimates, 16,600 CRS cases (range: 8300-62,250) were prevented by rubella vaccination from
2001 through 2010 in the United States. An estimated 1228 ASD cases were prevented by rubella vaccination in
the United States during this time period. Simulating a slight expansion in ASD diagnostic criteria in recent
decades, we estimate that a minimum of 830 ASD cases and a maximum of 6225 ASD cases were prevented.
Conclusions: We estimate that rubella vaccination prevented substantial numbers of CRS and ASD cases in the
United States from 2001 through 2010. These findings provide additional incentive to maintain high measles-
mumps-rubella (MMR) vaccination coverage.
Background
Rubella is a significant public health concern, as mater-
nal rubella infection during pregnancy can lead to con-
genital rubella syndrome (CRS) in the fetus [1]. CRS
comprises various defects, including deafness, cataracts,
encephalitis, heart abnormalities, and mental retardation,
among others [1,2]. The severity of CRS depends on the
time of infection during gestation, with the most serious
complications resulting from maternal infection in the
first trimester [2]. The largest rubella epidemic occurred
in the United States in the mid-1960s, when more than
2 0 , 0 0 0c h i l d r e nw e r eb o r nw i t hC R Sa f t e ra no u t b r e a k
of over 12.5 million cases of rubella during 1963-1965
[3-5]. Prenatal rubella infection also led to thousands of
fetal and infant deaths [6].
After the epidemic, several large-scale studies were
conducted on the so-called “rubella children,” establish-
ing a firm link between prenatal rubella infection and
congenital disorders [1,3,4]. Moreover, Chess found that
autism is one of the many outcomes associated with
CRS [7].
Using simple mathematical modeling, we calculated
the number of CRS and ASD cases that were prevented
by rubella vaccination in the United States from 2001
through 2010. We also performed sensitivity analyses to
examine how changes in certain model parameters affect
these prevention estimates.
Methods
In our simple model, the number of CRS cases pre-
vented by rubella vaccinationi nt h eU n i t e dS t a t e sd u r -
ing the ten-year period from 2001 through 2010 (X )i s
given by
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and the corresponding number of prevented ASD
cases (Y ) is given by
Y = X ∗ δ, (2)
where a and b are vaccine era and pre-vaccine era
CRS incidence in the US, respectively, and g is average
number of live births per year. The percentage of CRS
cases presenting with an ASD is denoted by δ .T h i s
model was chosen as a parsimonious representation of
the relationship between a reduction in CRS incidence
resulting from rubella vaccination and the incidence of
ASD.
Table 1 defines the parameters used to calculate the
numbers of CRS and ASD cases prevented by rubella
vaccination in the United States from 2001 through
2010. The estimate of vaccine era CRS annual incidence
(a ) was obtained by averaging CRS incidence in the
United States from 2001 to 2008 (most recent data) [8].
The number of live births was obtained from National
Vital Statistics Reports [9,10]. Data on the number of
live births per year (g ) were averaged over 2001-2009
(most recent data) and rounded to the nearest thousand.
Average values were used for vaccine era CRS incidence
and the number of live births because the annual values
changed very little over the respective time periods of
interest. Although vaccine era CRS incidence and live
birth data were only available through 2008 and 2009,
respectively, it was assumed that these data would
remain relatively constant through 2010.
Explicit data on pre-vaccine era CRS incidence in the
US are limited. The estimate of CRS incidence (b )a n d
lower and upper limits of this parameter were taken
from a study by Stray-Pedersen [11], which modeled
pre-vaccine era CRS incidence in Norway. In general,
the values of pre-vaccine era CRS incidence reported by
Stray-Pedersen are supported by research from other
countries, although individual estimates of CRS inci-
dence vary. Compared to the Norway study, CRS sur-
veillance in Jamaica returned the same overall estimate
of CRS incidence (4.0 cases per 10,000 births) [12]. A
slightly higher estimate of approximately 5 CRS cases
per 10,000 live births was reported from mathematical
modeling of pre-vaccine era CRS incidence in Australia
[13]. Mathematical modeling by Cutts and Vynnycky
[14] yielded overall estimates of CRS incidence in the
range of 17 cases per 10,000 live births in some develop-
ing regions. These estimates had very wide ranges [14],
however, and other studies have only reported such
high incidence rates during outbreaks [15]. Therefore,
t a k i n gac o n s e r v a t i v ea p p roach, we chose to use the
v a l u er e p o r t e df r o mN o r w a ya n dJ a m a i c a .T h eN o r w a y
and Jamaica studies also obtained the same estimate of
endemic CRS incidence (2.0 cases per 10,000 live births)
[11,12]. This value is similar to the estimated 0.81 to
1.27 CRS cases per 10,000 live births derived from a ret-
rospective review of medical records in Morocco [16]
and to the estimated 1 case per 10,000 live births
obtained from active surveillance in Yangon, Myanmar
[17]. In addition, a review by Cutts, et al. [15], summar-
ized estimates of epidemic CRS incidence from several
countries, ranging from 6 CRS cases per 10,000 live
births in Trinidad and Tobago to 22 cases per 10,000
live births in Panama. Within this range fell the Stray-
Pedersen estimate of 15 CRS cases per 10,000 live births
[11], and we included this value in our calculations.
The percentage of CRS cases presenting with an ASD
(δ ) was obtained from the Chess study of 243 preschool
children with CRS [7]. In the Chess study, eighteen chil-
dren had either the “full” syndrome (meeting all diag-
nostic criteria) or “partial” syndrome (meeting some but
not all diagnostic criteria) of autism, for a total preva-
lence of 7.4% [7]. Autism diagnosis was based on Kan-
ner’s original description of the disorder, published in
1943 [7]. According to Chess, Kanner’s classical criteria
for autism included “extreme autistic aloneness,” lan-
guage abnormalities, stereotypic relations to the envir-
onment, and a lack of affective human contact [7]. In
our model, the value of 7.4% was set as the overall esti-
mate of the percentage of CRS cases presenting with an
ASD, and lower and upper limits were set at 3.0% and
10.0%, respectively. These limits are designed to be con-
servative, considering that 1) quantitative data on the
Table 1 Model parameters, estimates, and lower and upper limits
Parameter Definition Lower Limit Estimate Upper Limit
a Vaccine era CRS incidence (cases per 10,000 live births)
a, b - 0.00 -
b Pre-vaccine era CRS incidence (cases per 10,000 live births)
c 2.0 4.0 15
g Live births per year (rounded to the nearest 1000)
b, d - 4,150,000 -
δ Percentage of CRS cases presenting with an ASD 3.0% 7.4% 10.0%
All data are from the United States unless otherwise specified in Methods.
a Averaged over 2001-2008.
b Parameter was not varied in sensitivity analyses (no lower and upper limit given).
c Lower limit, upper limit, and estimate correspond to endemic, epidemic, and overall CRS incidence, respectively.
d Averaged over 2001-2009.
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diagnostic criteria are broader and more inclusive than
Kanner’s classical criteria [18-20].
The estimates in Table 1 were used to calculate the
numbers of CRS and ASD cases prevented by rubella
vaccination from 2001 through 2010. A one-way sensi-
tivity analysis of the number of CRS cases prevented
was performed by varying pre-vaccine era CRS inci-
dence. It is somewhat unreasonable to extend an “ende-
mic” or “epidemic” estimate over a ten-year period
because rubella epidemics typically occur every six to
ten years in an unvaccinated population [21]. Neverthe-
less, we decided to employ the endemic estimate to
represent the “most conservative scenario,” in which
CRS incidence remains low in spite of a lack of rubella
vaccination. In contrast, extension of the epidemic esti-
mate represents the “least conservative scenario,” in
which rubella transmission is sustained at high levels in
an unvaccinated population. A two-way sensitivity analy-
sis of the number of ASD cases prevented was per-
formed by simultaneously varying pre-vaccine era CRS
incidence and the percentage of CRS cases presenting
with an ASD.
Results
Using equations 1 and 2 and the parameter estimates
given in Table 1 rubella vaccination prevented an esti-
mated 16,600 CRS cases and 1228 CRS-associated ASD
cases in the United States from 2001 through 2010. By
changing pre-vaccine era CRS incidence from 2.0 cases
per 10,000 live births (most conservative scenario) to 15
cases per 10,000 live births (least conservative scenario),
the estimated number of CRS cases prevented ranged
from 8300 to 62,250 (Table 2). Corresponding ASD pre-
vention estimates ranged from 614 to 4607 cases (Table
3). Varying the percentage of CRS cases presenting with
an ASD caused considerable, though less dramatic,
changes in ASD prevention estimates. When the percen-
tage of CRS cases presenting with an ASD was altered
from the lower limit of 3.0% to the upper limit of 10.0%,
an estimated 498 and 1660 ASD cases were prevented,
respectively (Table 3).
Combining variations in pre-vaccine era CRS inci-
dence and the percentage of CRS cases presenting with
an ASD, an estimated minimum of 249 ASD cases and
an estimated maximum of 6225 ASD cases were pre-
vented by rubella vaccination from 2001 through 2010
(Table 3). Due to the expansion of ASD diagnostic cri-
teria over time, using the upper limit of the percentage
of CRS cases presenting with an ASD may more accu-
rately reflect cases of ASD prevented using current diag-
nostic criteria. Employing the upper limit of the
percentage of CRS cases presenting with an ASD, an
estimated 1660 ASD cases (range: 830 to 6225 cases)
were prevented by rubella vaccination from 2001
through 2010.
Discussion
By preventing CRS, rubella vaccination has prevented
hundreds, and perhaps thousands, of ASD cases from
2001 through 2010 in the US. These results demonstrate
that the CRS-ASD association is not trivial, though the
prevented cases represent only a small fraction of cur-
rent ASD prevalence.
This study relies on estimates from Chess’s evaluation
of children with CRS. Fombonne, et al., published on the
link between autism and other medical disorders in 1997
[22]. The investigators found the rate of CRS among
autistic children to be 0.6%, but the association between
autism and CRS was not significant. However, given the
low overall prevalence of CRS in the population, the rela-
tively small sample size (174 children with autism) would
not have been sufficient to detect an association [22]. In
addition, the controls selected by Fombonne and collea-
gues were children with other “medical and developmen-
tal problems” and “intellectual deficits,” conditions which
are also associated with CRS [1,2,22]. The findings of
Fombonne and colleagues cannot be directly compared
to Chess’s estimates because Fombonne’s study examined
the relationship between CRS and autism following
implementation of rubella vaccination.
According to Castillo-Solórzano, et al. [23], “In the
United States the lifetime cost of treating a patient with
Table 2 One-way sensitivity analysis of the number of
CRS cases prevented by rubella vaccination, 2001-2010
Pre-Vaccine Era CRS Incidence Number of CRS Cases
Prevented
Endemic (2.0 cases/10,000 live
births)
8300
Overall (4.0 cases/10,000 live births) 16,600
Epidemic (15 cases/10,000 live
births)
62,250
Pre-vaccine era CRS incidence was varied to give estimates of the number of
CRS cases prevented under various rubella transmission scenarios.
Table 3 Two-way sensitivity analysis of the number of
ASD cases prevented by rubella vaccination, 2001-2010
Pre-Vaccine Era CRS
Incidence
Percentage of CRS Cases





Endemic 249 614 830
Overall 498 1228 1660
Epidemic 1868 4607 6225
Pre-vaccine era CRS incidence and the percentage of CRS cases presenting
with an ASD were varied simultaneously to give estimates of the numbers of
CRS-associated ASD cases prevented.
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CRS prevention estimates described in Results, rubella
vaccination saved the US between $1.7 billion and $12.5
billion by preventing CRS from 2001 to 2010. These
cost savings do not include the prevention of stress and
emotional suffering for individuals with CRS and their
families. Furthermore, since pre-vaccine era CRS inci-
dence was based on the number of live births, these
estimates do not account for stillbirths, miscarriages, or
induced abortions related to CRS.
Our study is subject to a number of limitations.
Because CRS and ASD prevention were estimated
through mathematical modeling, the accuracy of preven-
tion estimates is determined by the model parameters.
Of the model parameters, estimates of vaccine era CRS
incidence and the number of live births per year are
based on recent data from reliable sources and, there-
fore, are expected to be accurate. Although data on
these parameters were only available through 2008 and
2009, respectively, substantial changes in these para-
meters were not expected to occur before the end of the
ten-year period (2001 to 2010).
Our results are limited in that we had to rely on the
1971 Chess study [7] for estimates of the percentage of
CRS cases presenting with an ASD; no comparable data
were available elsewhere. However, this limitation
should lead to underestimation of ASD prevention,
since ASD diagnostic criteria have expanded since the
Chess study was conducted [20]. With the expansion of
Kanner’s classical criteria, we expect that more children
with CRS would be diagnosed with an ASD today. Addi-
tionally, we used data from other countries to estimate
pre-vaccine era CRS incidence in the United States
because specific data for the US were not available.
Among parents who choose not to have their children
vaccinated, vaccine safety concerns are often cited as the
reason for vaccine refusal [24]. In a survey of pediatri-
cians and family physicians in the United States in 2000,
69% of physicians perceived a “substantial increase” in
parental concerns about vaccine safety [25]. Regarding
MMR vaccination, a prospective cohort study of chil-
dren in the United Kingdom found that 74% of parents
of unvaccinated children made a “conscious decision”
not to have their children vaccinated with the combined
MMR vaccine [26]. Many of these parents claimed to be
concerned about vaccine safety, including the potential
association between the vaccine and autism. A smaller
fraction cited “negative media attention” as a reason for
their decision [26]. In the US, where monovalent rubella
vaccine is not available, MMR vaccination is the only
means of rubella vaccination.
Despite claims that MMR vaccination causes autism,
research does not support this association [27-30].
These claims are also ironic in light of our results,
which demonstrate that MMR vaccination (through the
rubella component of the vaccine) actually prevents
cases of autism and other ASDs through the prevention
of CRS. Although a disparity between public opinion
and scientific fact is evident, physicians and other
healthcare providers are in a prime position to address
the issue.
Conclusions
Our findings highlight the importance of rubella vacci-
nation in prevention of CRS and resultant autism spec-
trum disorders. These findings should be incorporated
into parental communication materials. Clinicians and
public health professionals should continue to educate
patients and the public about the benefits of rubella
vaccination.
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